INCRELEX (mecasermin), somatropin

ENDOCRINOLOGY - Update

Opinions on drugs - Posted on Oct 04 2017

Renewal of inclusion

INCRELEX (recombinant human IGF-1) has had marketing authorisation since 2007 in the long-term treatment of growth delays in children and adolescents aged 2 to 18 years with a severe primary IGF-1 deficiency.
Its effect on growth is variable and is difficult to assess, given the low amount of data available and the wide variability of effect from one patient to another.
It is the only treatment available for the management of severe primary IGF-1 deficiency, so the benefit must be assessed with regard to the frequency of its short-term adverse effects, in particular hypoglycaemia.

Substantial

minor

Therapeutic use

Évaluation des médicaments

All our publications

My account